Omega Fund Management, LLC

Est. AUM

$163.15B

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	Bicara Therapeutics Inc.	Common Stock	$47.58B	2392150	29.16%	SOLE
2	Nuvation Bio Inc.	Common Stock Class A	$34.67B	8081089	21.25%	SOLE
3	BridgeBio Oncology Therapeutics Inc.	Common Stock	$29.44B	3289661	18.05%	SOLE
4	Kestra Med Technologies Ltd	Common Stock	$20.37B	1022149	12.49%	SOLE
5	Beta Bionics Inc.	Common Stock	$13.19B	1316183	8.08%	SOLE
6	enGene Holdings Inc.	Common Stock	$5.97B	876357	3.66%	SOLE
7	Alumis Inc.	Common Stock	$5.31B	241255	3.26%	SOLE
8	Sana Biotechnology, Inc.	Common Stock	$2.43B	843750	1.49%	SOLE
9	ImageneBio, Inc.	Common Stock	$2.28B	455361	1.40%	SOLE
10	Replimune Group	Common Stock	$1.91B	248672	1.17%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.